In recent years efficacy of small molecule inhibitors of Chk1 has been tested in combination with DNA damaging agents in clinical trials against solid tumors, myeloid leukemia and small cell lung carcinoma with some favorable outcomes [31,32,33,34]. The gene discussed is CHEK1; the disease is small cell lung carcinoma.